What this study is
This study evaluates the feasibility and utility of contrast-enhanced ultrasound to provide real-time assessment of blood flow to the femoral head in infants undergoing surgical reduction for developmental dysplasia of the hip.
What's being tested
- Intraoperative contrast-enhanced ultrasound (CEUS)
Intervention · DIAGNOSTIC TEST
An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
- Lumason
Intervention · DRUG
Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
Study details
- Official title
- Use of Intraoperative Contrast-enhanced Ultrasound to Evaluate Femoral Head Perfusion in Infants With Developmental Dysplasia of the Hip at the Time of Surgical Reduction
- Sponsor
- Children's Hospital of Philadelphia
- Conditions
- Developmental Dysplasia of the Hip
- Enrolling
- 125 people
- Starts
- 2017-05-22
- Est. completion
- 2030-04
- Design
- Open-label, single group, Early Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 4 Months – 24 MonthsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Males or females between 4 months and up to and including 24 months of age at the time of surgery.
- Diagnosed with DDH.
- Failed conservative treatment, or present with late-diagnosed DDH (where conservative treatment would not be appropriate to initiate at their age), and are undergoing closed or open reduction and spica casting.
- Informed consent (parental permission)
You can't join if
- > 24 months of age at the time of surgery.
- Subjects with DDH who are successfully treated with conservative measures and do not require surgical reduction.
- Previous open hip reduction of the affected side
- Children with known complex congenital heart disease or unstable cardiopulmonary conditions (as noted in the package labeling for Lumason) including acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure or serious ventricular arrhythmias will be excluded.
- History of allergic reaction to Lumason, sulfur hexafluoride, sulfur hexafluoride lipid microsphere components, or other ingredients in Lumason (polyethylene glycol, distearoylphosphatidylcholine (DSPC), dipalmitoylphosphatidylglycerol sodium (DPPG-Ns), palmitic acid).Parental/guardian permission (informed consent) and if appropriate, child assent.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openThe Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- Wudbhav N. Sankar, MD · Contact215-590-1527sankarw@chop.edu
Recruiting
Study team
Sponsor
Children's Hospital of Philadelphia
Study ID 16-013583
Principal investigator
Wudbhav N Sankar, MD
Children's Hospital of Philadelphia
Principal investigator
Susan Back, MD
Children's Hospital of Philadelphia
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.